𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma

✍ Scribed by Christine H. Chung; Paula R. Pohlmann; Mace L. Rothenberg; Brian B. Burkey; Joel Parker; Kevin Palka; Joseph Aulino; Igor Puzanov; Barbara Murphy

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
751 KB
Volume
33
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Recurrent head and neck squamous cell carcinoma (HNSCC) remains a difficult cancer to treat. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG‐479 (monoclonal antibody against insulin‐like growth factor‐1 receptor [IGF‐1R]).

Methods

The clinical information was collected by a retrospective medical record review under an Institutional Review Board–approved protocol. From 4 tumors and 2 normal mucosal epithelia, global gene expression, and IGF‐1R and dihydrofolate reductase (DHFR) protein levels were determined.

Results

Effective target inhibition in the tumor was confirmed by the decreased protein levels of total and phospho‐IGF‐1R after treatment with AMG‐479. Decreased level of DHFR and conversion of a gene expression profile associated with cetuximab‐resistance to cetuximab‐sensitivity were also observed.

Conclusion

This suggests that the combination of AMG‐479 and MTX or cetuximab may be a promising therapeutic approach in refractory HNSCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010

📜 SIMILAR VOLUMES

Radiolabeled cetuximab: Dose optimizatio
Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model
✍ Bianca A.W. Hoeben; Janneke D.M. Molkenboer-Kuenen; Wim J.G. Oyen; Wenny J.M. Pe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 563 KB

## Abstract Noninvasive imaging of the epidermal growth factor receptor (EGFR) in head‐and‐neck squamous cell carcinoma could be of value to select patients for EGFR‐targeted therapy. We assessed dose optimization of ^111^Indium‐DTPA‐cetuximab (^111^In‐cetuximab) for EGFR imaging in a head‐and‐neck

Defects in the opioid growth factor rece
Defects in the opioid growth factor receptor in human squamous cell carcinoma of the head and neck
✍ Patricia J. McLaughlin; Brendan C. Stack Jr.; Roger J. Levin; Fred Fedok; Ian S. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

## Abstract ## BACKGROUND The endogenous opioid peptide, [Met^5^]‐enkephalin, termed opioid growth factor (OGF), interacts with its receptor (OGFr) to play a role as a constitutively expressed inhibitory growth factor in the proliferation of epithelial cells. This study compared protein and gene e

Gene amplification and overexpression of
Gene amplification and overexpression of epidermal growth factor receptor in squamous cell carcinoma of the head and neck
✍ Drs. Koichi Rikimaru; Drs. Keiko Tadokoro; Dr. Tadashi Yamamoto; Drs. Shoji Enom 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 552 KB

## Abstract The degree of gene amplification for epidermal growth factor receptor (EGFR) and its expression levels were examined in 4 cases of tumor lesions and their cell lines of human squamous cell carcinoma (SCC) of the oral cavity. The amplification was detected in 1 case (ZA), but not signifi

Dual inhibition of epidermal growth fact
Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: Reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma
✍ Chad E. Galer; Christina L. Corey; Zhuoying Wang; Maher N. Younes; Fernando Gome 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 572 KB

## Abstract ## Background Cutaneous squamous cell carcinoma (CSCC) is the second most common nonmelanoma skin cancer. Most of the approximately 250,000 cases occurring annually in the United States are small, nonaggressive, and cured by excision alone. However, a subset of these tumors which are d

Vascular endothelial growth factor C and
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck
✍ Csilla Neuchrist; Bohan M. Erovic; Allesandra Handisurya; Michael B. Fischer; Ge 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 379 KB 👁 1 views

## Abstract ## Background and Methods. VEGF proteins and their receptors are involved in tumor vessel neoformation. The third VEGF receptor, VEGFR3 (flt‐4) is important during both blood vessel development and lymphatic vessel formation. Because HNSCC preferentially metastasizes to regional lymph

Characterization, quantification, and po
Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas
✍ Dr. José Santini; Dr. Jean-Louis Formento; Dr. Mireille Francoual; Dr. Gérard Mi 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 661 KB

Epidermal growth factor (EGF) stimulates the growth of several types of epithelial tissues and possesses a strong mitogenic activity that is mediated through its cell surface receptor (EGFR). The aim of this study was to characterize EGFR and measure its levels in head and neck tumors biopsies (70 p